Dermatology, Ophthalmology, and GI: Why Investors Favor Procedure-Driven Specialties

Not all healthcare specialties have attracted private equity interest at the same pace, and the gap has become more pronounced as the market has matured. Procedure-driven specialties, most visibly dermatology, ophthalmology, and gastroenterology, have consistently led deal activity over the past decade. That pattern isn’t accidental, and for practice owners in these fields the reasons are worth understanding clearly rather than reading about in the abstract.

For a physician weighing whether to partner, build, or hold, the question isn’t really whether investor interest exists. It does, and in these three specialties it has been persistent through multiple market cycles. The more useful question is why these specialties underwrite so well, what buyers are actually paying for, and how a practice’s position inside those dynamics should shape its strategic options.

What “Procedure-Driven” Really Means for Valuation

A procedure-driven specialty is one where a meaningful portion of revenue comes from in-office or ambulatory procedures rather than evaluation and management visits alone. In dermatology, that means Mohs surgery, lesion excisions, biopsies, and a range of cosmetic procedures. In ophthalmology, cataract surgery is the anchor, supplemented by refractive procedures, injections, and premium lens offerings. In GI, screening and diagnostic colonoscopies and upper endoscopies form the procedural backbone, often paired with pathology and anesthesia.

The common thread is a revenue mix that is more predictable, more scalable, and less dependent on hospital systems than a purely cognitive practice. Procedural codes tend to reimburse at higher rates than office visits, the work is repeatable, and it can be performed in settings the practice or its partners control. From a buyer’s perspective, that combination makes cash flow easier to forecast and easier to grow.

Diversified Revenue Inside a Single Specialty

One of the underappreciated features of these three specialties is that each offers multiple revenue streams inside a focused clinical footprint. Professional fees, facility fees from ambulatory surgery centers, ancillary services, and in some cases meaningful cash-pay revenue can all sit inside the same platform.

Dermatology balances medical work with cosmetic and aesthetic services, often with an in-house pathology component. Ophthalmology pairs surgical volume with optical retail and premium lens upsells. GI combines procedural volume with ASC ownership, anesthesia, and pathology. For a buyer, this reduces dependence on any single payer or reimbursement lever and creates multiple paths to grow EBITDA after close. For a physician owner, it means the platform story isn’t just about the core clinical practice but also about how well the ancillary and cash-pay layers are built out at the time of a transaction.

Demographics That Support the Thesis

Demand in these specialties aligns with long-running demographic trends rather than short-term cycles. An aging population drives volume for skin cancer screening and treatment, cataract surgery and other vision care, and colorectal cancer screening and digestive disease management. Preventive care guidelines, including routine screening colonoscopies and regular skin examinations for at-risk patients, add a structural tailwind on top of the demographic one.

This matters for how buyers underwrite the business. A platform whose patient demand is tied to aging, screening guidelines, and medically necessary care tends to hold up better through economic cycles than one built primarily on elective or discretionary services. That resilience is part of what supports the valuations these specialties have commanded.

Where Scale Actually Produces Value

Procedure-driven specialties respond well to consolidation because the operational levers are concrete. Standardizing scheduling to increase procedural throughput, centralizing revenue cycle and payer contracting, negotiating supply and implant costs at a platform level, and building a recruiting engine that keeps associate pipelines full are all real sources of margin expansion.

The ASC piece deserves particular attention. Moving procedures from hospital outpatient departments to physician-owned or jointly owned ASCs typically improves both economics and patient experience, and scaled platforms have a clearer path to developing, acquiring, or joint-venturing ASCs than individual practices do. In GI and ophthalmology especially, ASC strategy is often the single largest post-close value creation lever, and buyers evaluate practices partly on how much of that opportunity is still available.

Ancillary Revenue and Vertical Integration

Alongside ASC development, vertical integration into ancillary services is a core part of the investment thesis in each of these specialties. The specifics vary by field:

• Dermatology: in-house pathology, cosmetic and aesthetic service lines, and branded skincare or product offerings
• Ophthalmology: optical retail, premium intraocular lens programs, and in-office imaging and diagnostics
• GI: ASC equity, anesthesia services, pathology, and in some cases infusion for IBD populations

Each of these captures revenue that would otherwise flow to an outside vendor and, done well, improves the coordination of patient care. For a practice going to market, the degree to which ancillaries are already in place, and the room that remains to develop them, directly affects how buyers value the business.

Resilience as Reimbursement Shifts

The reimbursement environment continues to move, and procedure-driven specialties aren’t immune. Codes get revalued, site-of-service differentials change, and commercial contracting dynamics vary by market. What these specialties do offer is a revenue base anchored in procedural codes, much of which is tied to preventive care and medically necessary services supported by clinical guidelines. That makes drastic, across-the-board cuts less likely than in areas more exposed to policy volatility.

Buyers know this, and it’s part of why these specialties have continued to trade at premium multiples even as capital has become more selective across healthcare services broadly.

Why Platforms, Not Just Practices

Private equity activity in these fields has consistently been about platform building rather than one-off practice acquisitions. The objective is to assemble regional or national groups that can achieve meaningful market density, negotiate effectively with payers, recruit top physician talent, and create a business that either a larger sponsor or a strategic acquirer will want at the next stage.

That shape of the market matters for physicians evaluating their options. In several markets, the platforms are well established, which affects both the pricing of individual practices and the quality of partnership a seller can expect. In other markets and submarkets, platform formation is still underway, and the earliest practices in often secure more favorable terms, including on rollover equity, governance, and growth participation.

How Practice Owners Should Think About Timing and Structure

For a physician in dermatology, ophthalmology, or GI, the current environment offers real options, but not all deals are the same. The headline valuation number is only one piece of what determines whether a transaction was a good one five years later. The more consequential questions tend to include:

• Clinical autonomy and the scope of decisions that remain with physicians after close
• Compensation structure, both base and incentive, and how it changes over time
• Governance, including board composition, approval rights, and how disputes are resolved
• Rollover equity terms, expected growth, and the realistic path to a second transaction
• Ancillary and ASC participation, and how existing physician ownership is treated

Timing is part of the calculus as well. In a market where a platform has already been assembled, the competitive dynamics of a sale are different from those in a market where the first platform is still being built. Neither is automatically better, but the right approach to a process depends on which situation a practice is in.

About The Bloom Organization

The Bloom Organization is a healthcare-focused, sell-side M&A advisory firm with more than thirty years of experience representing physician groups, healthcare operators, and middle-market healthcare businesses. Securities transactions are conducted through Bloom Securities, LLC, a member of FINRA and SIPC.

Our advisory work in procedure-driven specialties includes:

• Representing dermatology, ophthalmology, and GI practices in sale processes and platform partnerships
• Positioning practices for private equity, strategic, and physician-led platform buyers
• Structuring transactions that balance upfront proceeds, rollover equity, and long-term economics
• Advising on ancillary, ASC, and vertical integration strategies ahead of a transaction
• Guiding owners through governance, compensation, and integration terms with platform partners

If you’re a practice owner in one of these specialties and want to understand how your group would be positioned in today’s market, we’d welcome the conversation.